Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Pyridostigmine Bromide (Mestinon; Regonol; Kalimin) is a parasympathomimetic and a reversible cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. Pyridostigmine Bromide hase been approved for millitary use during the Gulf War as a pretreatment to protect troops from the harmful effects of nerve agents.
References |
Neuroscience.2013 Aug 29;246:391-6;Luminescence.2011 Nov-Dec;26(6):510-7.
|
---|
Molecular Formula |
C9H13BRN2O2
|
|
---|---|---|
Molecular Weight |
261.12
|
|
CAS # |
101-26-8
|
|
Related CAS # |
Pyridostigmine-d6 bromide;2375858-08-3;Pyridostigmine-d3 bromide
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
[Br-].O(C(N(C([H])([H])[H])C([H])([H])[H])=O)C1C([H])=C([H])C([H])=[N+](C([H])([H])[H])C=1[H]
|
|
InChi Key |
VNYBTNPBYXSMOO-UHFFFAOYSA-M
|
|
InChi Code |
InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
|
|
Chemical Name |
(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate;bromide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (382.97 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8297 mL | 19.1483 mL | 38.2966 mL | |
5 mM | 0.7659 mL | 3.8297 mL | 7.6593 mL | |
10 mM | 0.3830 mL | 1.9148 mL | 3.8297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05334485 | Not yet recruiting | Drug: Pyridostigmine Bromide Other: Placebo |
Postoperative Ileus | Stefan Holubar MD MS FACS, FASCRS | December 2024 | Phase 2 Phase 3 |
NCT05110417 | Terminated | Drug: Pyridostigmine Bromide | Pompe Disease | Eastern Virginia Medical School | May 20, 2021 | Phase 4 |
NCT05110417 | Recruiting | Drug: Pyridostigmine Bromide 60 Milligrams (mg) |
Dysphonia, Spastic Dysphonia Laryngeal Dystonia |
Eastern Virginia Medical School | May 20, 2021 | Phase 4 |
NCT05603715 | Recruiting | Drug: Pyridostigmine Bromide | Parkinson Disease Constipation |
University of Vermont Medical Center | August 10, 2022 | Phase 2 |
NCT02941328 | Completed | Drug: Pyridostigmine Drug: Placebo |
Spinal Muscular Atrophy SMA Kugelberg-Welander Disease |
UMC Utrecht | December 2015 | Phase 2 |